ArticlePLOS global public health2025
COVID-19 vaccine coverage among adults in Sarlahi District of Nepal in 2022.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nepal launched its COVID-19 vaccination campaign in January 2021 through the COVID-19 Vaccines Global Access (COVAX) facility. Vaccine coverage, especially in low- and middle-income countries (LMICs), is measured using administrative-level data; however, this source is often subject to biases and limitations. We conducted a household survey in rural Sarlahi District, Nepal, to estimate COVID-19 vaccine coverage and assess associations with participant characteristics among adults. The quantitative household survey was conducted from August to December 2022 in four municipalities among 362 adults aged 18 years and older. The survey collected demographic data, vaccination status and vaccination accessibility details. Descriptive analyses included a summary of vaccination coverage, vaccine card availability, drop-out rate, and vaccine manufacturer. Multivariable regression modeling was used to analyze factors associated with completing the primary vaccination series. Three-quarters of participants (74.6%) completed at least the primary series (51.9% only completed the primary series, 22.7% were also boosted). Vaccine card retention was 86% among those with at least one dose. Odds of completing the primary series increased with age (31-50 yrs, adjusted odds ratio (aOR) = 3.07, 95% CI: (1.67, 5.8) and 51 + years, aOR = 4.75, 95% CI: (2.06, 11.9) compared to 18-30 years). Wealthier groups had higher odds of completing the primary series than the poorest quartile (wealth quartile 2, aOR = 3.04, 95% CI: (1.41, 6.80); wealth quartile 3, aOR = 2.18, 95% CI: (1.05, 4.62); wealth quartile 4, aOR = 2.32, 95% CI: (1.06, 5.17)). Despite moderate primary series coverage and high card retention, booster coverage remained low. The population has exhibited a mix-and-match approach to COVID-19 vaccination, likely due to availability and accessibility. While the emergency stage of the pandemic has ended, lack of adequate vaccine coverage increases the immunity gap for a virus that continues to circulate and evolve.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.